Market Data 
Markets
Replies to post #218741 on Biotech Values
07/26/18 12:55 PM
Bracing for a flood of costly prescription claims for the drug, Aimovig, large insurers such as Anthem Inc have set requirements for patients to document how they suffer from a defined number of headaches each month, and show that they have tried older migraine drugs first.
Others have made it even harder. Plans including Blue Cross/Blue Shield in Florida, Pennsylvania and Kansas confirmed with Reuters that they will only cover prescriptions from - or in consultation with - a neurologist or headache specialist, and specifically a member of the United Council for Neurologic Subspecialties. Only around three percent of U.S. neurologists have such certification…
04/04/19 2:49 PM
Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market migraine prevention drug Aimovig, and keep the profits for itself.
…Amgen, in an emailed statement, said it is seeking to terminate the collaboration agreements with Novartis and obtain damages, but termination would not be effective until the litigation is resolved.
In its complaint, Novartis said it has spent at least $870 million on Aimovig since it began collaborating in August 2015 with Amgen, which previously controlled rights to the drug. Novartis accused Amgen of trying to wrongfully back out of their collaboration agreements based on the pretext that the Swiss company’s Sandoz unit was working with Alder Biopharmaceuticals Inc on a possible Aimovig rival.
… “The [ALDR] program about which Amgen has complained is being terminated,” Novartis said, and the lack of a breach means Amgen’s April 2 notice terminating the [Aimovig] collaboration agreements should be deemed void.
AI
